2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Updated
Solicitation from the National Institutes of Health. Due Dec 8, 2026, 3:00 PM (UTC-5), 33 days left.
| Solicitation number | HHS-NIH-NIAID-BAA2026-1 |
|---|---|
| Agency | National Institutes of Health |
| Office | National Institutes of Health Niaid |
| Notice type | Solicitation |
| Set-aside | None |
| Trade (NAICS) | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715) |
| Product or service code | AN12 |
| Posted | Nov 4, 2026 |
| Response deadline | Dec 8, 2026, 3:00 PM (UTC-5) (33 days left) |
| Add the deadline to | Google Calendar · Apple / Outlook (.ics) |
Bid documents (3)
- Attachment 17: Technical Proposal Readiness Checklist for Research Area 002 89 KB
- Solicitation 1.2 MB
- Solicitation Amendment 1 248 KB
Paid members download every document from this page, or buy this bid alone.
Description
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens.
NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (aspr.hhs.gov/PHEMCE/2024-PHEMCE...), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (cdc.gov/antimicrobial-resistanc...).
In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation.
An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach.
Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses.
The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial.
Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery.
Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) cdc.gov/viral-hemorrhagic-fever...
Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered.
Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area.
A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated
The description continues in the official notice.
Contracting contact
- Contracting Officer: Alexandra Buck, JD · [email protected]
As published on the official notice. Ask questions in writing and before any questions deadline the notice sets.
Is your business small enough?
For NAICS 541715, a business counts as small if it has no more than 11 employees (SBA size standard, with exceptions in the notes). This notice is set aside, so only businesses under that size, or in the named program, can bid. SBA table, current as of Oct 15, 2026.
Notice history
- Oct 9, 2026: Solicitation Due Dec 8, 2026, 3:00 PM (UTC-5)
Companies that win this kind of work
Federal contractors paid for research and development in the physical, engineering, and life sciences work, who also hold NIH contracts (last 12 months): possible competitors, or partners to team with.
- Booz Allen Hamilton Inc $791.0 million in this trade
- Leidos Biomedical Research Inc $776.3 million in this trade
- Deloitte Consulting LLP $372.4 million in this trade
- Battelle Memorial Institute $147.4 million in this trade
- Westat, Inc. $88.7 million in this trade
About the buyer
The National Institutes of Health awarded $5.9 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.
Research and Development in the Physical, Engineering, and Life Sciences contracts right now
There are 272 open government contract opportunities in this trade (NAICS 541715), 43 posted in the last 7 days; 30% are set aside for small businesses. The agencies buying the most are Department of the Air Force, Department of the Army and Defense Advanced Research Projects Agency (DARPA). Most of the work with a stated place is in Maryland, District of Columbia and Virginia. A notice in this trade gives a median of 52 days from posting to deadline; this one gives 34 days.
All open research and development in the physical, engineering, and life sciences contracts
Coming up in this trade
Planned contracts from the agencies' procurement forecasts, often months before a solicitation. Plans can change.
Recent awards in this trade
- Airborne Holdings Inc $232,060 · Department of the Navy · Nov 3, 2026
- UNIVERSITY OF MAINE SYSTEM Orono ME $632,224 · Department of the Army · Nov 3, 2026
- Yale Univ NEW Haven $8.6 million · Department of Veterans Affairs · Oct 29, 2026
- ICF Incorporated, L.L.C. $2.9 million · Environmental Protection Agency · Oct 29, 2026
- SOUTHWEST RESEARCH INSTITUTE San Antonio TX $19.9 million · National Aeronautics and Space Administration · Oct 29, 2026
From the award notices agencies publish.